AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

029 Group SE

M&A Activity Jun 25, 2002

4544_rns_2002-06-25_afbbbf03-7e38-4ba5-8141-48b1a082b655.html

M&A Activity

Open in Viewer

Opens in native device viewer

News Details

Ad-hoc | 25 June 2002 07:30

Rhein Biotech N.V. english

Official Takeover Bid by Berna Biotech Launched Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Official Takeover Bid by Berna Biotech Launched Rhein Biotech N.V., specialist in the development, production and marketing of vaccines, has announced that Berna Biotech AG (Berne, Switzerland) has launched its official takeover bid. The merger by acquisition will take place according to the terms of the tender agreed upon by both management teams and boards of directors: for each Rhein Biotech share, shareholders will receive 1.42 Berna Biotech shares plus Euro 33.75 in cash. All members of the Rhein Biotech supervisory board and the board of managing directors as well as the major shareholder Green Cross Corporation (together holding approximately 21 percent of Rhein Biotech’s share capital) have already agreed to tender their shares to Berna Biotech for the agreed compensation. The acceptance period is open until 12.00 pm (noon), on the 15th of July, 2002. The tender document outlining the terms and conditions is available at http://www.b-r-merger.com. Alternatively, please contact the Rhein Biotech Shareholder Hotline +49(0)-180-5112001 or Merrill Germany GmbH, Grüneburgweg 14-18, D-60322 Frankfurt / Main for a free copy end of ad-hoc-announcement (c)DGAP 25.06.2002 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: For more information on Rhein Biotech visit http://www.rheinbiotech.com or contact the following: Company Contact: Marcel Jacobs Communication Manager Rhein Biotech NV T: +31 (0)43 / 35 67 894 F: +31 (0)43 / 35 67 899 E: [email protected] Media Contact: Carsten Heinrichs IR-Consultant vom Hoff Kommunikation GmbH T: +49 (0)211 / 515 805 12 F: +49 (0)211 / 515 805 55 E: [email protected] ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: NEMAX 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 250730 Jun 02

Talk to a Data Expert

Have a question? We'll get back to you promptly.